Heterogeneous blood pressure treatment effects on cognitive decline in type 2 diabetes: A machine learning analysis of a randomized clinical trial
Diabetes, Obesity and Metabolism, ISSN: 1463-1326
2024
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Aim: We aimed to identify the characteristics of patients with diabetes who can derive cognitive benefits from intensive blood pressure (BP) treatment using machine learning methods. Materials and Methods: Using data from the Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes (ACCORD-MIND) study, 1349 patients with type 2 diabetes who underwent BP treatment (intensive treatment targeting a systolic BP <120 mmHg vs. standard treatment targeting <140 mmHg) were included in the machine learning analysis. Seventy-nine variables correlated with diabetes and cognitive function were used to build the causal forest and causal tree models for identifying heterogeneous BP treatment effects on cognitive decline. Results: Our analyses identified four variables including urinary albumin-to-creatinine ratio (UACR, mg/g), Framingham 10-year cardiovascular risk score (FRS, %), triglycerides (TG, mmol/L) and diabetes duration, that categorized the participants into five subgroups with different risk benefits for cognitive decline from BP treatments. Subgroup 1 (UACR ≥65 mg/g) had an absolute risk reduction (ARR) of 15.36% (95% CI, 5.01%–25.46%) from intensive versus standard BP treatment (hazard ratio [HR], 0.36; 95% CI, 0.18–0.73). Subgroup 2 (UACR <65 mg/g, FRS ≥26%, TG <2.3 mmol/L and diabetes duration ≥9 years) had an ARR of 14.74% (95% CI, 4.56%–24.59%) from intensive versus standard BP treatment (HR, 0.34; 95% CI, 0.15–0.77). No significant benefits were found for other subgroups. Conclusions: Patients with type 2 diabetes with high UACR, or with low UACR and low TG, but high predicted cardiovascular risk and long diabetes duration were likely to derive cognitive benefits from intensive BP treatment.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know